Erasca, Inc.
Financials
Valuation Metrics
Erasca, Inc.'s Market Cap is $5.17B. At end of 2025 it was $1.05B. Ranked #1301 of 3,121 in US market (top 42%), #440 of 1,463 on NASDAQ (top 30%), #79 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 30%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $5.17B | US#1,301/3,121 Sec#79/266 |
| Revenue | $0.00 | US#2,889/3,121 Sec#196/266 |
| Net Income | $-287M | US—/3,121 Sec—/266 |
| Total Assets | $435M | US#2,822/3,121 Sec#178/266 |
| Net Assets | $362M | US#2,441/3,121 Sec#146/266 |
| Employees | 103 | US#2,621/3,121 Sec#177/266 |
| Value | ||
| P/B | 14.28x | US#2,733/3,121 Sec#208/266 |
| FCF Yield | -1.90% | US—/3,121 Sec—/266 |
| Profitability | ||
| ROE | -79.37% | US#2,769/3,121 Sec#193/266 |
| ROA | -66.02% | US#3,027/3,121 Sec#235/266 |
| Financial Health | ||
| Debt Ratio | 20.22% | US#232/3,121 Sec#79/266 |
| Total Debt | $45M | US#2,636/3,121 Sec#158/266 |
| FCF | $-98M | US#2,627/3,121 Sec#142/266 |
| Cash | $43M | US#2,652/3,121 Sec#236/266 |
| Current Ratio | 8.29x | US#312/3,121 Sec#96/266 |
| Performance | ||
| 1Y Return | 689.84% | US#3/3,121 Sec#1/266 |
| 1M Return | -18.26% | US#2,818/3,121 Sec#220/266 |
| From 52W High | -39.17% | US#2,366/3,121 Sec#181/266 |
| 1Y MDD | -59.46% | US#2,767/3,121 Sec#212/266 |
| Trading | ||
| Volume | 6,689,921 shares | US#235/3,121 Sec#18/266 |
| Trading Value | $100M | US#781/3,121 Sec#49/266 |
| Per Share | ||
| EPS | $-0.82 | US—/3,121 Sec—/266 |
| BPS | $1.03 | US#2,696/3,121 Sec#205/266 |
Company Info
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.